{
  "id": 12217533,
  "title": "Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy Research",
  "url": "https://urgent.news/2026/10/05/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-05T19:33:39.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/flicking-the-switch-five-scientists-honored-at-2026-warren-alpert-foundation-symposium-for-hemoglobinopathy-research/"
  },
  "original_language": "en",
  "account": "On a recent day in Boston, the Warren Alpert Foundation recognized five distinguished scientists from Harvard Medical School and the National Institutes of Health for their groundbreaking work in hemoglobinopathy research. Stuart Orkin, alongside his former students Vijay Sankaran and Daniel Bauer, along with Swee-Lay Thein and John Tisdale, all from the NIH, were hailed for their pivotal discoveries regarding BCL11A, a key regulator of fetal-to-adult hemoglobin switch. This breakthrough paved the way for the development of the first CRISPR medicine, Casgevy, which treats sickle cell disease (SCD) and thalassemia.\n\nThe symposium's keynote address was given by Jennifer Doudna, PhD, the 2020 Nobel laureate, who emphasized the importance of a profound biological understanding in drug development. Doudna commended patient volunteers like Victoria Gray and Jimi Olaghere, whose participation was crucial for the success of Casgevy, now approved in 39 countries and widely covered by insurance. Despite challenges such as toxicity, cost, infrastructure, and global accessibility, Doudna remained optimistic about the future of CRISPR therapy, particularly through novel approaches like in vivo gene editing.\n\nThe symposium, organized by Ed Benz, MD, highlighted Orkin's 33-year journey from thalassemia research to BCL11A discovery, and Thein's early insights into beta-thalassemia's mild, transfusion-independent variants. Orkin stressed the potential of BCL11A as a therapeutic target, noting its stability and unique dose-response properties, and the importance of developing affordable, scalable therapies for SCD and thalassemia.",
  "summary": "Stuart Orkin, MD, and his former trainees Vijay Sankaran, MD, PhD, and Daniel Bauer, PhD, were joined by Swee-Lay Thein, MD, PhD, and John Tisdale, MD, both at the NIH. Their contributions helped to identify BCL11A as a major regulator of the fetal-to-adult hemoglobin switch. The post Flicking the Switch: Five Scientists Honored at 2026 Warren Alpert Foundation Symposium for Hemoglobinopathy…",
  "key_points": [
    "Five scientists honored for hemoglobinopathy research at 2026 Warren Alpert Foundation Symposium.",
    "Casgevy, first CRISPR medicine for SCD and thalassemia, developed from BCL11A research."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}